Outlook Therapeutics Inc-Lytenava (Bevacizumab Gamma) acquires 10-year market exclusivity in the EU
Outlook Therapeutics Inc-Lytenava（Bevacizumab Gamma）在欧盟获得十年的市场独家经营权
Outlook Therapeutics Inc-Lytenava (Bevacizumab Gamma) acquires 10-year market exclusivity in the EU
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.